Preliminary Human Trials of F230 Tablets

PHASE1RecruitingINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2026

Conditions
Pulmonary Hypertension
Interventions
DRUG

F230 tablets

"SAD: A1: F230 tablets 3mg;A2: F230 tablets 6mg;A3: F230 tablets 12mg;A4: F230 tablets 20mg;A5: F230 tablets 30mg;A6: F230 tablets 40mg .~MAD: B1: F230 tablets 6mg; B2: F230 tablets 12mg; B3: F230 tablets 20mg; Studies on the effects of food on drugs:Group K-C: The first cycle was fasting administration, and the second cycle was postprandial administration;C-K:The first cycle was given after meals, and the second cycle was given on an empty stomach."

Trial Locations (1)

430022

RECRUITING

Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Hubei

All Listed Sponsors
lead

Beijing Continent Pharmaceutical Co, Ltd.

INDUSTRY

NCT06899815 - Preliminary Human Trials of F230 Tablets | Biotech Hunter | Biotech Hunter